Diabetes treatment lowers PromarkerD risk score: Results presented at Australasian Diabetes Congress
Proteomics International Laboratories Ltd (Proteomics International; ASX: PIQ) is pleased to...
PromarkerD Shows Improved Predictive Ability and Robustness
Proteomics International (PI) is pleased to provide an update on its clinical studies for PromarkerD, the company’s breakthrough test for the prediction of diabetic kidney disease.
PromarkerD is showing improved predictive ability and robustness, and Managing Director Dr Richard Lipscombe is presenting these findings today at an international conference on food and health in New Delhi, India.